YAP signaling in gastric cancer-derived mesenchymal stem cells is critical for its promoting role in cancer progression

ZHAOJI PAN1*, YIQING TIAN1*, BIN ZHANG1*, XU ZHANG1, HUI SHI1, ZHAOFENG LIANG1, PEIPEI WU1, RONG LI1, BENSUAI YOU1, LUNYU YANG1, FEI MAO1, HUI QIAN1 and WENRONG XU1,2

1Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013; 2The Affiliated Hospital, Jiangsu University, Zhenjiang, Jiangsu 212000, P.R. China

Received May 11, 2017; Accepted July 24, 2017

DOI: 10.3892/ijo.2017.4101

Abstract. Cancer-associated mesenchymal stem cells (MSCs) are critically involved in tumor development and progression. However, the mechanisms of action for MSCs in cancer remain largely unknown. Herein, we reported that the expression of Yes-associated protein 1 (YAP) was higher in gastric cancer derived mesenchymal stem cells (GC-MSCs) than that in bone marrow derived MSCs (BM-MSCs). YAP knockdown not only inhibited the growth, migration and invasion, and stemness of GC-MSCs, but also suppressed their promoting effect on gastric cancer growth in vitro and in vivo. In addition, the interference of YAP expression in GC-MSCs also attenuated the promoting role of gastric cancer cells in endothelial cell tube formation and migration. Mechanistically, YAP knockdown reduced the activation of β-catenin and its target genes in gastric cancer cells by GC-MSCs. Taken together, these findings suggest that YAP activation in GC-MSCs plays an important role in promoting gastric cancer progression, which may represent a potential target for gastric cancer therapy.

Introduction

Gastric cancer is the fourth most common cancer and second leading cause of cancer-related deaths worldwide (1-4). Although great efforts have been made, the current treatments for gastric cancer are still not efficacious (5). Increasing evidence has shown that the microenvironment plays important roles in gastric cancer progression (6,7). Mesenchymal stem cells (MSCs) are a critical component of cancer microenvironment. We have previously reported the isolation of MSCs from gastric cancer tissues (GC-MSCs) and have demonstrated that these cells could promote gastric cancer growth and metastasis (8-10). However, the underlying mechanisms responsible for the promoting role of GC-MSCs in gastric cancer progression remain unknown.

The Hippo pathway plays a critical role in organ size control, tissue homeostasis and early embryonic cell specification (11). Yes-associated protein 1 (YAP) is the central component of this pathway. YAP has been recently identified as an oncoprotein that is overexpressed in many cancers, including gastric cancer, liver cancer, lung cancer, breast cancer, and ovarian cancer among others (12-14). The knockdown of YAP inhibits gastric cancer cell proliferation, migration, invasion, and metastasis (15,16), suggesting that YAP plays important roles in the development and progression of gastric cancer.

In addition to tumor cells, YAP could also regulate the microenvironmental cells. For instance, YAP could modulate cell-cell and cell-matrix interactions (17) as well as the production of secretory proteins such as amphiregulin [AREG; an epidermal growth factor (EGF) family member], cysteine-rich angiogenic inducer 61 (CYR61), and connective tissue growth factor (CTGF) (18-20). Moreover, YAP expression in the microenvironmental cells also affect tumor progression. YAP is required for the tumor-promoting role of CAFs in matrix remodeling and angiogenesis (17,21), indicating that YAP pathway may affect tumor progression by regulating both tumor cells and microenvironmental cells.

Mesenchymal stem cells (MSCs) have been suggested as a key player in the tumor microenvironment. We have previously shown that MSCs isolated from gastric cancer tissues have a strong promoting role in gastric cancer progression (8-10). However, the detailed molecular mechanism is not clear. In this study, we aimed to investigate whether YAP is involved in the promoting effect of GC-MSCs on gastric cancer progression. We found that YAP silencing significantly suppressed the promoting effects of GC-MSC on gastric cancer growth in vitro and in vivo, which may be associated with the decreased activation of β-catenin in gastric cancer cells.

Materials and methods

Subjects. The gastric cancer tissues were collected from 15 patients with gastric adenocarcinoma between August...
2015 and February 2016 in the Affiliated Hospital of Jiangsu University. There were 8 male and 7 female patients with ages ranging from 48 to 71 years old (median, 59 years old). The patients were diagnosed by pathological analyses according to the UICC (International Union Against Cancer) criteria. The use of clinical sample was approved by the Ethics Committee of Jiangsu University and written informed consent was obtained from all the patients.

Isolation and culture of MSCs from gastric cancer tissues. GC-MSCs were isolated as previously described (22,23). Fresh gastric cancer tissues were washed with phosphate-buffered saline (PBS) to remove the blood. Then, the tissues were cut into 1-3 mm²-sized pieces and floated in Dulbecco’s modified Eagle’s medium with low glucose (LG-DMEM, Invitrogen, Carlsbad, CA, USA) containing 15% fetal bovine serum (FBS, Invitrogen), penicillin (100 U/ml) and streptomycin (100 µg/ml). The pieces of gastric cancer tissues were cultured at 37°C in humidified atmosphere with 5% CO₂. After culturing for 10 days, the colonies of fibroblast-like cells appeared. When the cells reached ~80% confluence, they were trypsinized and re-plated into larger culture flasks at a 1:3 split ratio. The GC-MSCs at passage 4 were used for subsequent experiments.

Cell culture. GC-MSCs were cultured in LG-DMEM with 15% FBS. The human GC cell lines SGC-7901 (moderately differentiated), HGC-27 (undifferentiated) and MGC-803 (poorly differentiated) were purchased from the Cell Bank of the China Academy of Sciences (Beijing, China) and maintained in the RPMI-1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% FBS. Human umbilical vein endothelial cell line EA.hy926 was purchased from the Cell Bank of the China Academy of Sciences and maintained in high-glucose DMEM supplemented with 10% FBS. All the cells were cultured at 37°C in humidified atmosphere with 5% CO₂.

Lentiviral knockdown of YAP. The lentiviral expression vector containing the shRNA sequence (Sigma) was selected for target-specific gene silencing. The shRNA sequences targeting Yap were as follows: forward, CCGGGCCACCAAGCTTGA TAAAAAGCTCAGTTTATTCATCTGTTGGTGCTTT TTG; reverse, AATTCAAAGGCACAAAGCTGATAA GAGACTCGAGTCTTATCTAGCTGTTGGCC. Control shRNAs were constructed using scrambled sequences. The shRNA lentiviral vectors were generated by ligating the vector Tet-pLKO-puro; these lentiviral vectors were produced using a lentivirus packaging mix (ViraPower, Invitrogen). In addition, stable cell line was obtained after selection with 1 µg/ml of puromycin (Invitrogen) for 5 days. The efficiency of YAP knockdown was evaluated by using real-time quantitative RT-PCR and western blotting.

Generation of conditioned medium. Control and YAP knockdown GC-MSCs were plated in 6-well plates at a density of 1x10⁵ cells/well and cultured in 1.6 ml complete LG-DMEM with 15% FBS. After 72 h, the conditioned medium (CM) was collected, centrifuged to remove cellular debris (800 g for 5 min) and passed through a 0.22-µm filter (Millipore, Billerica, MA, USA) and stored in -20°C until use. Gastric cancer cell-derived CM was generated in a similar manner.

RNA extraction and real-time RT-PCR. Total RNA was isolated from cells and tissues using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions, and equal amount of RNA was used for RT-PCR. The StepOne Real-Time system was used for quantitative mRNA detection. The expression of target genes was normalized to that of β-actin. The expression of each gene was measured by formula 2⁻ΔΔCt. The primers used in this study were produced by Invitrogen (Shanghai, China) and the sequences are listed in Table I.

Western blotting. GC-MSCs and gastric cancer cells were homogenized and lysed in RIPA buffer supplemented with proteinase inhibitors. Equal amounts of proteins were separated on a 12% SDS-PAGE gel. Following electrophoresis, the proteins were transferred to the PVDF membrane, blocked in 5% (w/v) non-fat milk and incubated with the primary antibodies at 4°C overnight. The sources of antibodies were as follows: anti-GAPDH (Kangcheng, China); anti-YAP, anti-vimentin, anti-Bcl2, and anti-Bax (Biosworld Technology, Louis Park, MN, USA); anti-β-catenin (Cell Signaling Technology, Beverly, MA, USA); anti-E-cadherin, and anti-N-cadherin (Santa Cruz Biotecnology, Inc., Santa Cruz, CA, USA); anti-Ki67 (BOSTER, China). The membrane was washed with Tris-buffered saline/Tween 3 times and incubated with the secondary antibodies (Biosworld Technology) at 37°C for 1 h. The signals were visualized by using a Lumina cresendo western horseradish peroxidase substrate (Millipore). The dilution factor for the primary and secondary antibodies was 1:1,000, respectively.

Colony formation assay. GC-MSCs and gastric cancer cells were seeded into 6-well plates (2x10³ cells/well) and incubated at 37°C in a 5% CO₂-humidified incubator for 8 days. SGC-7901 cells were treated with 2 ml complete medium and GC-MSCs derived CM (1:1, v/v). The medium was changed at 3-day intervals. At the end of the incubation period, the cultures were fixed with 4% paraformaldehyde and stained with crystal violet. The results are the mean values of three independent experiments.

Cell migration and invasion assays. GC-MSCs (5x10⁴ cells/well), gastric cancer cells treated with GC-MSCs derived CM (1x10⁵ cells/well), and EA.hy926 treated with CM of gastric cancer cells (5x10⁴ cells/well) were plated into the top chamber of Transwell (8.0-µm pore sized) with serum-free L-DMEM, and medium containing 10% FBS was placed into the bottom chamber. After incubation at 37°C in a 5% CO₂-humidified incubator for 12 h, the cells that remained at the upper surface of the membrane were removed with a cotton swab. The filters were fixed in 4% paraformaldehyde for 30 min, stained with crystal violet for 15 min, and photographed. The cells were observed under a microscope, and at least five fields of cells were assayed for each group. Each assay was repeated in triplicate. For cell invasion assay, the Transwell chambers were coated with 200 µl of Matrigel at a dilution of 1:5 in serum-free medium and the incubation time was extended to 24 h. The remaining procedure was the same as that of cell migration assay. The number of migrated and invaded cells was counted under a microscope (Ti-S, Nikon) and five fields were randomly selected.
The antibodies used were anti-β-catenin (1:50; Cell Signaling Technology), anti-E-cadherin, anti-N-cadherin (1:50; Santa Cruz Biotechnology), and anti-Ki67 (1:100; Boster, China). Ki67 staining is usually evaluated by counting positive cells of the total cell count (nucleus is stained by Ki67 antibody). Both cytosol and nucleus of the cells were positively stained for β-catenin protein.

**Cell apoptosis assay.** For cell apoptosis assay, a FITC Annexin V apoptosis detection kit (Vazyme, China) was used. SGC-7901 cells treated with GC-MSCs derived CM were trypsinized, washed in PBS and stained according to the manufacturer's instructions. The stained cells were analyzed by using flow cytometry (BD Accuri C6).

**Animal model.** Eighteen male BALB/c nu/nu mice (Laboratory Animal Center of Shanghai, Academy of Science, China) aged 4-6 weeks were randomly divided into 3 groups (6 mice/group). The animals were injected subcutaneously with untreated SGC-7901 cells (blank group), control GC-MSCs-CM treated SGC-7901 cells (sh-Ctrl CM group), and YAP knockdown GC-MSCs-CM treated SGC-7901 cells (sh-YAP CM group) (1.5x10^6 cells in 200 µl PBS) into the right back side of mice. Tumor volumes were measured every 2 days using calipers according to the modified ellipsoidal formula: (length x width^2)/2. The tumors were removed after injection for 28 days. The experiment protocols were approved by the Animal Use Committee of Jiangsu University.

**Statistical analyses.** All the data are presented as mean ± standard deviation (SD). The statistically significant differences between groups were assessed by using analysis of variance (ANOVA) or t-test by Prism software (GraphPad, San Diego, USA). P-value <0.05 was considered statistically significant.

**Results**

**YAP knockdown inhibits the proliferation of GC-MSCs.** As one of the key components of tumor microenvironment (TME), MSCs have been found to play critical roles in tumor progression (24,25). We have previously demonstrated that GC-MSCs promote gastric cancer growth more efficiently than adjacent non-cancerous gastric tissue-derived MSCs (GCN-MSCs) and bone marrow-derived MSCs (BM-MSCs) (10,23). We hypothesized that YAP overexpression and activation is involved in the superior promoting role of GC-MSCs in gastric cancer growth. Thus, we compared YAP expression between GC-MSCs and BM-MSCs. The results of western blotting showed that the expression level of YAP in GC-MSCs was higher than that in BM-MSCs (Fig. 1A). Then, we used shRNA to knock down YAP in GC-MSCs and explored the effects of YAP knockdown on the proliferation of GC-MSCs (Fig. 1B). The results of colony formation assay showed that there were less colonies in YAP shRNA (shYAP) group than that in control group (Fig. 1C). The results of immunfluorescent staining revealed that there were more Ki67-positive cells in control group than that in shYAP group (Fig. 1D). The expression of PCNA was decreased in shYAP GC-MSCs compared to that in control GC-MSCs (Fig. 1B). Together, these results suggest that YAP knockdown inhibited the proliferation of GC-MSCs.

### Table I. The sequences of the primers.

| Genes            | The sequences of the primers                  |
|------------------|-----------------------------------------------|
| β-actin          | Forward 5'-GACCTGTACGCAACACAGT-3' Reverse 5'-CTCAGGAGGCAATAATGCT-3' |
| E-cadherin       | Forward 5'-CCGATTGCCACATACACT-3' Reverse 5'-TTGGCCTAGAAGTTGTAAG-3' |
| N-cadherin       | Forward 5'-AGTCAACTGCAACAGT-3' Reverse 5'-AGGTCCTGCTTCCACTCAT-3' |
| Bax              | Forward 5'-CACAGACAGATCAT-3' Reverse 5'-GATCAGTTCGGCACCACCTTG-3' |
| BCL-2            | Forward 5'-CTGGGAGAAGAGGTTACGATAA-3' Reverse 5'-CCACACGAACTCAAAGG-3' |
| MMP2             | Forward 5'-CTGAAATCCATGTAGGAGAG-3' Reverse 5'-TACTTCACAGCGACCATCT-3' |
| MMP9             | Forward 5'-AGCTTTGCTCGAGGACG-3' Reverse 5'-GGACTCTGCAAGATCTCAG-3' |
| Slug             | Forward 5'-CTTGGTGTTCGCAAGACAC-3' Reverse 5'-TCCATGCTTGGTCAGCAGCT-3' |
| Oct4             | Forward 5'-TTGAGGCTCTGTCAAGCTTAG-3' Reverse 5'-GCCGTTAGACAGCACCAC-3' |
| SOX2             | Forward 5'-ACACCAATCCCCTTCCACCT-3' Reverse 5'-GCAAATCTCTGTCAAGCTC-3' |
| Nanog            | Forward 5'-CCTGATTCTTCCACAGTCC-3' Reverse 5'-TGCTATTCTCGGCGGCTTG-3' |
| CD44             | Forward 5'-TCACAGTGGAGAAGAGAC-3' Reverse 5'-CAT TG CATGTTGTCAC-3' |
| PDGF             | Forward 5'-CTCAGGCGAGATGACTTGA-3' Reverse 5'-CCACACATCCTGCCCTTAA-3' |
| VEGF             | Forward 5'-CTCCTGCTCGTCTACCTCAC-3' Reverse 5'-ATCTGATGTTGATGTTGGA-3' |
| IL-8             | Forward 5'-GCTCTGTGGTGAAAGGTGAGT-3' Reverse 5'-TCTGTTGTTGGCAGGTGT-3' |

**Endothelial tube formation assay.** The endothelial tube formation assay was conducted according to the manufacturer's protocol (BD Biosciences, Franklin Lakes, NJ, USA). Matrigel (50 µl) was added to each well of a 96-well plate and allowed to polymerize. EA.hy926 cells (2x10^4) plated on Matrigel was treated with the conditional medium of gastric cancer cells. After incubation for 12 h at 37°C, the cells were viewed under a microscope and photographed. The number of formed tubes was counted under a microscope and five fields were randomly selected.

**Immunohistochemistry.** Immunohistochemistry was used to detect protein expression in tumor tissues sections. The antibodies used were anti-β-catenin (1:50; Cell Signaling Technology), CD31 (1:50; Bioworld Technology), anti-E-cadherin, anti-N-cadherin (1:50; Santa Cruz Biotechnology), and anti-Ki67 (1:100; Boster, China). Ki67 staining is usually evaluated by counting positive cells of the total cell count (nucleus is stained by Ki67 antibody). Both cytosol and nucleus of the cells were positively stained for β-catenin protein.
Figure 1. YAP knockdown inhibits the proliferation of GC-MSCs. (A) Western blotting for protein levels of YAP in BM-MSC and GC-MSC. (B) Western blotting for protein levels of PCNA, and YAP in GC-MSCs (control) and GC-MSCs (ShYAP). RT-PCR analysis of YAP expression in GC-MSCs (control) and GC-MSCs (ShYAP). ***P<0.001. (C) Colony formation assay in GC-MSCs (control) and GC-MSCs (ShYAP). (D) Immunofluorescence analysis revealed the expression level of Ki67 in GC-MSCs (control) and GC-MSCs (ShYAP). Magnification, x200; scale bar, 100 µm.

Figure 2. YAP knockdown inhibits the migration and invasion of GC-MSCs. (A) RT-PCR analysis of MMP2 and MMP9 expression in GC-MSCs (control) and GC-MSCs (ShYAP). *P<0.05. (B) Transwell migration assay histogram of migration cell number in GC-MSCs (control) and GC-MSCs (ShYAP). Magnification, x100; scale bar, 50 µm. (C) Transwell invasion assay histogram of invasion cell number in GC-MSCs (control) and GC-MSCs (ShYAP). Magnification, x100; scale bar, 50 µm. ***P<0.001.
YAP knockdown inhibits the migration and invasion of GC-MSCs. We next investigated the effects of YAP knockdown on the migratory and invasive abilities of GC-MSCs. The expression of MMP2 and MMP9 was detected by using quantitative RT-PCR. YAP shRNA reduced the expression of MMP2 and MMP9 in GC-MSCs (Fig. 2A). Consistently, the number of cells migrating towards the lower surface of the chamber in the Transwell migration assay was lower in shYAP group than that in control group (Fig. 2B). Similar change was also observed in the matrigel invasion assay (Fig. 2C). Thus, these data suggest that YAP knockdown reduces the migratory and invasive abilities of GC-MSCs.

The knockdown of YAP suppresses EMT and stemness of GC-MSCs. We further investigated whether YAP affects mesenchymal-epithelial transition (MET) and stem cell properties of GC-MSCs. As shown in Fig. 3, YAP knockdown led to an increased expression of E-cadherin and a decreased expression of N-cadherin, vimentin and slug in GC-MSCs (Fig. 3A and B).

To explore whether YAP maintains stem cell properties in GC-MSCs, we detected the expression of stem cell markers including Sox-2, Oct-4, and Nanog. As shown in Fig. 3C, YAP knockdown led to the reduced expression of Sox-2, Oct-4, and Nanog. Collectively, these results suggest that YAP may regulate the stem cell properties of GC-MSCs.

YAP knockdown in GC-MSCs reduced its promoting effect on gastric cancer cell growth in vitro. We further investigated whether YAP knockdown could affect the promoting role of GC-MSCs in the proliferation of gastric cancer cells. The results of cell colony formation assay showed that treatment with the conditioned media (CM) from control GC-MSCs increased the number of colonies of SGC-7901, HGC-27 and MGC-803 cells (Fig. 4A). However, when cultured with CM from shYAP GC-MSCs, the number of cell colonies was significantly decreased. The number of Ki67-positive cells was increased in SGC-7901 cells treated with CM from shYAP GC-MSCs (sh-Ctrl CM group) but was decreased when treated with CM from shYAP GC-MSCs (sh-YAP CM group) (Fig. 4B). The results of western blotting showed that the expression of PCNA was increased in sh-Ctrl CM group but was decreased in sh-YAP CM group (Fig. 4C). There was no significant change in the expression of the anti-apoptotic protein Bcl-2 and the pro-apoptotic protein Bax in gastric cancer cells when treated with CM from either control GC-MSCs or shYAP GC-MSCs (Fig. 4C). In addition, YAP knockdown had minimal effects on the apoptosis of SGC-7901 cells (Fig. 4D). In summary, YAP knockdown in GC-MSCs reduced its promoting role in the proliferation of gastric cancer cells.

YAP knockdown in GC-MSCs inhibits its promoting role in the migration and invasion of gastric cancer cells. We investigated the effects of YAP knockdown on the promoting role of GC-MSCs in gastric cancer cell migration and invasion. The gastric cancer cells in shYAP CM group exhibited lower migratory and invasive capacities than that in sh-Ctrl CM group (Fig. 5A-D).
PAN et al: YAP MAINTAINS THE PRO-TUMOR EFFECTS OF MSCs IN GASTRIC CANCER

YAP knockdown in GC-MSCs inhibits its promoting role in the pro-angiogenic ability of gastric cancer cells. Angiogenesis is considered as a critical step for cancer development and progression. MSCs can favor the formation of tumor blood vessels and thus promote tumor growth and metastasis (26). As shown in Fig. 6, the incubation with CM from sh-YAP GC-MSCs dramatically decreased the expression of VEGF, PDGF, and IL-8 in gastric cancer cells compared to incubation with CM from control GC-MSCs (Fig. 6A). The results of tube formation assay demonstrated that the supernatant of sh-YAP CM group had reduced ability to promote endothelial cell tube formation than that of sh-Ctrl CM group (Fig. 6B). Endothelial cell migration is critical for angiogenesis. The results of Transwell migration assay showed that the CM from sh-YAP CM group had decreased ability to promote the migration of endothelial cells compared to the CM from sh-Ctrl CM group (Fig. 6C). Taken together, these results reveal that YAP knockdown in GC-MSCs inhibits its promoting role in the pro-angiogenic ability of gastric cancer cells.

YAP knockdown in GC-MSCs reduced its promoting effect on the activation of β-catenin in gastric cancer cells. β-catenin is
an important pathway in gastric carcinogenesis (27-31). MSCs enhanced the activation of β-catenin signaling in cancer. We then examined the role of YAP in MSC-mediated regulation of β-catenin signaling in gastric cancer cells. As shown in Fig. 7A, the expression of β-catenin was lower in sh-YAP CM group compared to that in sh-Ctrl CM group. Moreover, the expression of β-catenin downstream genes including cyclin D and CD44 was lower in sh-YAP CM group than that in...
sh-Ctrl CM group (Fig. 7B). Collectively, these results suggest that YAP knockdown in GC-MSCs reversed their activating role in β-catenin signaling in gastric cancer cells.

YAP knockdown in GC-MSCs inhibits its promoting role in gastric cancer growth in vivo. To confirm the in vitro results, SGC-7901 cells treated with CM from control and shYAP GC-MSCs were used to establish mouse xenograft tumor models. The images of xenograft tumors are shown in Fig. 8A. The tumors in sh-YAP CM group grew slower and were smaller, and the average tumor weight was lower than that in sh-Ctrl CM group (Fig. 8B). The expression of Ki67 and β-catenin in tumor tissues was determined by using immunohistochemistry. We found that the percentage of Ki67-positive cells was 24.0% in sh-YAP CM group and was 92.1% in sh-Ctrl CM group. The expression of β-catenin in the nucleus was stronger in sh-Ctrl CM group than that in sh-YAP CM group (Fig. 8C). The decreased expression of E-cadherin observed in sh-Ctrl CM group were reversed in sh-YAP CM group (Fig. 8C). Moreover, CD31 expression in sh-YAP CM group was significantly lower than that in sh-Ctrl CM group (Fig. 8D). Taken together, these results suggest that YAP knockdown in GC-MSCs reversed its promoting role in gastric cancer growth in vivo.

Discussion

Over the past decades, the relation between MSCs and tumor has attracted increasing attention (8,25,32). Although the previous studies have shown an important role of MSCs...
in cancer (33-35), the detailed mechanisms responsible for the regulation of tumor-resident MSCs are not clear. The Hippo/YAP pathway has recently been reported to play important roles in human cancers (36-38). As a critical component of Hippo pathways, YAP could exert oncogenic activities with its paralog transcriptional co-activator with a PDZ-binding motif (TAZ) (39). The expression of YAP in gastric cancer tissues is closely associated with poorer overall survival of patients. RUNX3 is reported to function as a tumor suppressor by downregulating YAP in the progression of cancer (40). Moreover, VGLL4 could inhibit the expression of YAP, and a peptide is found to act as a YAP antagonist therapy against gastric cancer by mimicking VGLL4 function (41).

The interaction between MSCs and tumor cells is critical for tumor progression (21,42). GC-MSCs enhanced the proliferation and migration of gastric cancer cells as well as facilitate tumor angiogenesis (10). In this study, we identified that YAP signaling was critical for the promoting roles of GC-MSCs in gastric cancer progression. We reported that YAP knockdown led to the inhibition of the growth, migration, and invasion of gastric cancer cell lines with poorer overall survival of patients. RUNX3 is reported to function as a tumor suppressor by downregulating YAP in the progression of cancer (40). Moreover, VGLL4 could inhibit the expression of YAP, and a peptide is found to act as a YAP antagonist therapy against gastric cancer by mimicking VGLL4 function (41).

The interaction between MSCs and tumor cells is critical for tumor progression (21,42). GC-MSCs enhanced the proliferation and migration of gastric cancer cells as well as facilitate tumor angiogenesis (10). In this study, we identified that YAP signaling was critical for the promoting roles of GC-MSCs in gastric cancer progression. We reported that YAP knockdown led to the inhibition of the growth, migration, and invasion of gastric cancer cell lines with poorer overall survival of patients. RUNX3 is reported to function as a tumor suppressor by downregulating YAP in the progression of cancer (40). Moreover, VGLL4 could inhibit the expression of YAP, and a peptide is found to act as a YAP antagonist therapy against gastric cancer by mimicking VGLL4 function (41).

The oncogenic roles of YAP in cancer has recently been a research focus (43-45). In this study, we reported that gastric cancer cells grow slower when incubated with CM from YAP knockdown GC-MSCs. However, YAP knockdown in GC-MSCs have no effects on the apoptosis of gastric cancer cells. It was reported that YAP could promote the growth of cholangiocarcinoma by interacting with TEAD transcription factors (49). Sun and colleagues found that YAP could enhance the proliferation, migration, and invasion of gastric cancer cells in vitro and in vivo (16). The decreased YAP signaling inhibited tumor growth and metastasis by reducing the expression of PCNA, MMP-2, MMP-9, and cyclin D1 (45). In the present study, we found that YAP knockdown in GC-MSCs abrogated its promoting roles in gastric cancer cell proliferation, migration, and invasion, indicating an important role of YAP signaling in the tumor-promoting effect of GC-MSCs in gastric cancer. Moreover, YAP could also promote angiogenesis in human cancer (46). We observed that endothelial cells exposed to the supernatant from sh-YAP CM-treated gastric cancer cells showed decreased tube formation and migration abilities, which may be associated with the decreased expression of pro-angiogenic factors including VEGF, PDGF, and IL-8 in gastric cancer cells. These findings suggest a potent role of YAP in GC-MSCs in regulating tumor angiogenesis. Metastasis is associated with increased cell migration and invasion. The β-catenin pathway is reported to affect the migration and invasion of cancer cells (47). In our study, YAP knockdown in GC-MSCs inhibited its promoting role in the activation of β-catenin and the migration and invasion of gastric cancer cells. Thus, YAP signaling in GC-MSCs may promote gastric cancer metastasis through an indirect activation of β-catenin pathway in gastric cancer cells.
β-catenin pathway contributes to cancer progression by regulating the proliferation, invasion, and metastasis of cancer cells (47-50). Our results revealed that the increased expression of β-catenin in sh-Ctrl CM group was abrogated in the sh-YAP CM group. In addition, the expression of β-catenin downstream genes CD44 and cyclin D1 was also decreased in sh-YAP CM group compared to sh-Ctrl CM group. These findings suggest that YAP signaling modulates GC-MSC-mediated activation of β-catenin in gastric cancer cells. We have recently reported that YAP critically regulates the activity of β-catenin (51). YAP knockdown may affect the components of CM from GC-MSCs, which thus abrogates the activation of β-catenin signaling in tumor cells. However, the exact factors responsible for this role need to be identified in future studies.

In conclusion, we demonstrated that YAP knockdown in GC-MSCs not only inhibits their proliferation, migration and invasion, but also suppresses their promoting roles in the proliferation, migration, invasion and pro-angiogenesis of gastric cancer cells in vitro and in vivo. Disturbing the expression of YAP in GC-MSCs inhibits its derived CM-induced activation of β-catenin in gastric cancer cells. In conclusion, YAP expression in GC-MSCs plays an important role in promoting gastric cancer progression, which may provide a novel avenue for gastric cancer therapy.

Acknowledgements

This study was supported by the Major Research Plan of the National Natural Science Foundation of China (grant...
References

1. Tan YK and Fielding JW: Early diagnosis of early gastric cancer. Eur J Gastroenterol Hepatol 18: 821-829, 2006.
2. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, Malvezzi M and La Vecchia C: Recent patterns in gastric cancer: A global overview. Int J Cancer 125: 666-673, 2009.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
4. Cormier-Robert K, Charnet P, Million E, Aunan J, Zhang Y, Liu J, Cao Y, Guo J, Du J, et al: CXCL1-chemokine (C-X-C motif) receptor 2 signaling stimulates the recruitment of bone marrow-derived mesenchymal cells into diffuse-type gastric cancer stroma. Am J Pathol 180: 3028-3039, 2016.

17. Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary E, Charras G, et al: Mechanotransduction and YAP-dependent matrix remodeling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 15: 637-646, 2013.

Zhang J, Ji Y, Yu M, Overholtzzer M, Smolen GA, Wang R, Brugge JS, Dyon JJ, Haber DA: YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 11: 1444-1450, 2009.

Fujii J, Toyoda T, Nakanishi H, Yatabe Y, Sato A, Matsuda Y, Ito H, Murakami H, Kondo Y, Kondo E, et al: TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med 209: 479-494, 2012.

Mo JS, Park HW and Guan KL: The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep 15: 642-656, 2014.

Zhang T, Lee YW, Rui YF, Cheng TY, Jiang XH and Li G: Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. Stem Cell Res Ther 4: 70, 2013.

Yi W, Xu W, Qian H, Zhu W, Yan Y, Zhou H, Zhang X, Xu X, Li J, Chen Z, et al: Mesenchymal stem cell-like cells derived from human gastric cancer tissue. Cancer Lett 274: 30, 2009.

18. Zhang J, Ji JY, Yu M, Overholtzzer M, Smolen GA, Wang R, Brugge JS, Dyon JJ, Haber DA: YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 11: 1444-1450, 2009.

Zhang J, Ji JY, Yu M, Overholtzzer M, Smolen GA, Wang R, Brugge JS, Dyon JJ, Haber DA: YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 11: 1444-1450, 2009.
Zuo QF, Zhang R, Li BS, Zhao YL, Zhuang Y, Yu T, Gong L, Li S, Xiao B and Zou QM: MicroRNA-141 inhibits tumor growth and metastasis in gastric cancer by directly targeting transcriptional co-activator with PDZ-binding motif, TAZ. Cell Death Dis 6: e1623, 2015.

Quo Y, Lin SJ, Chen Y, Voon DC, Zhu F, Chuang LS, Wang T, Tan P, Lee SC, Yeoh KG, et al: RUNX3 is a novel negative regulator of oncogenic TEAD-YAP complex in gastric cancer. Oncogene 35: 2664-2674, 2016.

Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, He F, Wang Y, Zhang Z, Wang W, et al: A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 25: 166-180, 2014.

Liu C, Liu Y, Xu XX, Guo X, Sun GW and Ma XF: Mesenchymal stem cells enhance the metastasis of 3D-cultured hepatocellular carcinoma cells. BMC Cancer 16: 566, 2016.

Ehmer U and Sage J: Control of proliferation and cancer growth by the Hippo signaling pathway. Mol Cancer Res 14: 127-140, 2016.

Yagi H, Asanoma K, Ohgami T, Ichinoe A, Sonoda K and Kato K: GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer. Oncogene 35: 4471-4480, 2016.

Zhang J, Wang G, Chu SJ, Zhu JS, Zhang R, Lu WW, Xia LQ, Lu YM, Da W and Sun Q: Loss of large tumor suppressor 1 promotes growth and metastasis of gastric cancer cells through upregulation of the YAP signaling. Oncotarget 7: 16180-16193, 2016.